Going Mobile - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Going Mobile
Seven Reasons Why Pharmaceutical Makers Are Adopting Mobile Technology

Pharmaceutical Technology

Photo: SYCLO
Increasingly, pharmaceutical companies worldwide are recognizing the cost savings and efficiency increases of using mobile technology to streamline operations, increase customer satisfaction, and improve top-line revenues. Companies can adopt mobile technology throughout the entire spectrum of their business—from sales and customer service to research and discovery, manufacturing, and distribution.

Mobile technologies help streamline business processes at all stages of the pharmaceutical life cycle. Many pharmaceutical companies use mobile technology to eliminate paperwork, meet 21 CFR Part 11 and Prescription Drug Marketing Act (PDMA) guidelines, electronically capture signatures, streamline inspections, enable accurate data capture, and meet other performance objectives.

At the start of the product life cycle, researchers must ensure their cleanrooms and laboratories meet compliance standards for contamination control, health and safety, hazardous chemical handling, and documentation. Firms are using mobile technology to enable paperless inspections that capture data on-site. Paperless inspections allow companies to take immediate action and store information for compliance and management decisions.

Figure 1
More and more, companies are using mobile devices for electronic data capture in clinical trials. This capability gives firms immediate access to trial data and allows them to monitor events, derive accurate data, perform instant validation, and reduce data-entry time. A review of randomized controlled trials that compared data capture with handheld devices against paper methods demonstrated that data quality and timeliness increased with the use of handheld devices. Subjects also preferred using the handheld devices, and their convenience likely increased subjects' adherence to protocols (1).

As an effective way to meet US Food and Drug Administration requirements, pharmaceutical companies have incorporated the e-signature and e-validation features of mobile technology applications into their production processes to create an unalterable, accurate electronic trail of accountability for inspectors to review. Mobile technology enables companies to track temperatures, data points, and inspection points to ensure a safe and secure work environment and to keep production on schedule.

Many pharmaceutical firms use mobile technologies to make thousands of measurements that are the basis of decisions that affect drug quality. Calibrating instrumentation helps maintain product integrity throughout the production process. And to ensure that strict regulatory compliance and adherence to quality specifications be maintained, technicians using handhelds can capture production data. Mobile technology also makes calibration data easily accessible to others who must monitor it, such as plant managers.

Taking the platform approach.
For these reasons, many pharmaceutical companies use handheld computers to ensure that measurement instruments are correctly calibrated. One pharmaceutical manufacturer uses mobile technology to track equipment temperatures, data points, and inspection points.

A major reason that some companies are implementing mobile technology is that it allows the large-scale optimization of manufacturing tasks (i.e., maximizing the time, capital, and equipment used and streamlining raw-material handling and production). One pharmaceutical company, for example, labeled more than 8000 assets with barcodes that its technicians could track with its mobile technology application. As a result, the company has increased the number of completed work orders for preventive maintenance, and managers are better able to account for the work done on those assets. Such efficiency gains are not possible with a paper-based system. Of course, a hurdle for most pharmaceutical companies is to validate data capture for 21 CFR Part 11 for compliance reporting. Mobile solutions can ensure that vital information is electronically captured to keep accurate repair and operating records for regulatory agencies.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here